丁苯酞对急性脑梗死患者血清白介素6的影响

目的：观察丁苯酞对急性脑梗死患者白介素6（IL-6）、超敏CRP、血小板聚集率的影响,探讨神经功能缺损与IL-6等的相关性。方法：80例急性脑梗死患者,随机分为治疗组（40例）和对照组（40例）,20名健康体检者作为正常对照组。治疗组和对照组均采用常规治疗,治疗组加用丁苯酞200 mg,每日3次口服,连用14 d。在治疗前和治疗后30 d对治疗组和对照组脑梗死患者进行NIHSS评分,治疗后3个月进行mRS评分以观察神经功能恢复情况。在治疗前和治疗后7 d测定超敏CRP、IL-6、血小板聚集率水平,同时对神经功能缺损评分与超敏CRP、IL-6、血小板聚集率的相关性进行分析。结果：治疗前治疗组和对照组的超敏CRP、IL-6、血小板聚集率水平均高于正常对照组,（P〈0.05）,治疗后7 d两组超敏CRP、IL-6、血小板聚集率水平均较治疗前下降,且治疗组的超敏CRP、IL-6、血小板聚集率水平较对照组下降更加明显,（P〈0.05）。治疗后两组的神经功能损伤程度评分均较治疗前明显下降,且与对照组相比,治疗组治疗后的评分较前下降更为显著（P〈0.05）。急性脑梗死患者NIHSS评分、mRS评分的下降与超敏CRP、IL-6及血小板聚集率的下降呈正相关（P〈0.05）。结论：丁苯酞通过减轻炎症反应和抑制血小板聚集以促进神经功能的恢复,对急性脑梗死早期有显著治疗作用。

Effects of butylphthalide on interleukin-6 in patients with acute cerebral infarction

Objective：To observe the effects of Butylphthalide on Interleukin-6 （IL-6）,high-sensitivity C-reactive protein （hs-CRP） and platelet aggregation rate in patients with acute cerebral infarction,and to explore the correlation between neurological impairment and IL-6.Methods： Eighty cases of patients with acute cerebral infarction were randomly divided into treatment group and control group.Twenty healthy subjects were selected as normal controls.The treatment group and the control group received conventional treatment,while the former was additionally given 200mg oral Butylphthalide thrice daily for 14 days. The National Institutes of Health Stroke Scale （ NIHSS） scores of patients with acute cerebral infarction in the treatment group and the control group were assessed at baseline and at 30 days after treatment.The mRS scores were assessed at 3 months after the treatment to investigate the neurological function recovery. The levels of IL-6 and hs-CRP and the platelet aggregation rate were measured at baseline and at one week after the treatment.Meanwhile,the correlations between neurological impairment and hs-CRP,IL-6 and platelet aggregation rate were analyzed. Results：The levels of hs-CRP,IL-6 and platelet aggregation rate in the treatment group and the control group were higher than those in the normal control group before the treatment （P〈0.05）.At 7 days after the treatment,the levels of hs-CRP,IL-6 and platelet aggregation rate in these two groups decreased compared with baseline.Besides,the reduction in these parameters from baseline were greater in the treatment group than in the control group,with statistical difference （ P〈0.05） . The neurological impairment severity scores in the two groups decreased from baseline after the treatment. Compared with the control group,treatment group showed greater reduction in the scores after the treatment （ P〈0.05）.The reduction in NIHSS and mRS scores were positively correlated with the reduction in hs-CRP,IL-6 and platelet aggregati